Reena Karthaمشاهده پروفایل
دانشیار
- Rare Diseases
- Pharmacology
- Oxidative Stress
- +۵ مورد دیگر
Dr. Reena Kartha is an Associate Professor in the Department of Experimental and Clinical Pharmacology at the University of Minnesota College of Pharmacy, where she also serves as the Associate Director of Translational Pharmacology. Her research focuses on rare diseases, particularly investigating the pathophysiological role of oxidative stress and inflammation in rare disorders occurring due to inherited errors of metabolism. Dr. Kartha directs the Center for Orphan Drug Research and leads multiple translational research projects with pharmaceutical industry partners including Sanofi, Takeda, and Pfizer. Dr. Kartha's educational background includes: Molecular and Cellular Biology from Indian Institute of Science, Bangalore, India Biotechnology from Tamil Nadu Agricultural University, India Agriculture from Kerala Agricultural University, India Dr. Kartha's research program is dedicated to deciphering the pathophysiological role of oxidative stress and inflammation in rare disorders, particularly those caused by inherited metabolic errors. Her laboratory conducts studies to elucidate the mechanism of action of drugs using cellular and animal models, with the long-term goal of developing new therapies or optimizing existing treatments for rare diseases. A significant focus of her work involves the identification of novel protein- or miRNA-based biomarkers for early diagnosis, prognosis, and treatment response using patient-derived samples. Her expertise spans molecular pharmacology, biomarker analysis, and rare inherited metabolic disorders, particularly Gaucher disease and adrenoleukodystrophy. Analysis of Dr. Kartha's recent publications reveals a strong focus on rare diseases, particularly Gaucher disease and related lysosomal storage disorders. Her work consistently explores the role of oxidative stress and inflammation in these conditions, and investigates potential therapeutic interventions such as N-acetylcysteine. There is a clear progression from basic mechanistic studies to clinical applications, with an increasing emphasis on biomarker discovery and validation. Her research demonstrates significant collaboration with clinical teams and pharmaceutical industry partners, reflecting the translational nature of her work. Dr. Kartha has received numerous awards and recognitions for her contributions to research and mentorship: CTSI Outstanding Junior Mentor of the Year (2017) NIH Rare Disease Clinical Research Network (RDCRN) Certificate Training Scholar (2016-17) Lysosomal Disease Network Clinical Fellow (2016-18) Senior Research Fellowship from Council for Scientific and Industrial Research, New Delhi, India M.S. Swaminathan award for best scholar in Biotechnology, Coimbatore, India Merit scholarship from Department of Biotechnology, New Delhi, India Dr. Kartha is actively involved in mentoring students and junior researchers, as evidenced by her CTSI Outstanding Junior Mentor award. She leads multiple significant research projects funded by pharmaceutical companies including Sanofi, Takeda, and Pfizer, with a focus on translational pharmacology for rare diseases. Her current projects include investigating extracellular vesicles as potential biomarkers and therapeutic targets in Gaucher disease, and exploring the use of antioxidant or anti-inflammatory medications to mitigate oxidative stress in Type 1 Gaucher Disease. Dr. Kartha directs research activities at the Center for Orphan Drug Research within the Department of Experimental and Clinical Pharmacology. Her laboratory collaborates with multiple research teams across the University of Minnesota and with external partners in the pharmaceutical industry. Her work frequently involves interdisciplinary teams including pharmacologists, biochemists, clinicians specializing in rare diseases, and bioinformaticians for biomarker analysis.









